Nanoviricides | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.1.

EBIT: As of FY2026 Q1, the actual value is USD -1.808 M.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the company reported a net loss of - $1,785,058, compared to a net loss of - $3,126,811 for the same period in 2024.
• Research and Development Expenses: Decreased to $993,066 for the three months ended September 30, 2025, from $1,933,091 for the same period in 2024, primarily due to a decrease in outside lab fees previously required for clinical studies.
• General and Administrative Expenses: Decreased to $803,619 for the three months ended September 30, 2025, from $1,234,743 for the same period in 2024, due to a decrease in professional fees associated with investor outreach.

Cash Flow

• Net Cash Used in Operating Activities: - $1,593,855 for the three months ended September 30, 2025, compared to - $2,594,863 for the same period in 2024.
• Net Cash Used in Investing Activities: - $84,317 for the three months ended September 30, 2025, compared to - $46,764 for the same period in 2024.
• Net Cash Provided by Financing Activities: $1,245,319 for the three months ended September 30, 2025, compared to $1,710,138 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to advance NV-387 into Phase II clinical trials for multiple indications, including MPox, Measles, and RSV, with the goal of addressing unmet medical needs in viral infectious diseases. The company is also exploring non-dilutive funding and partnerships to support these initiatives.
• Non-Core Business: The company is actively seeking non-dilutive grants and contracts, as well as debt or equity financing, to fund its operations and research and development plans, including human clinical trials for its various drug candidates.
• Priority: The company is focusing on achieving several milestones, including the filing of clinical trial applications for NV-387, obtaining orphan drug designations, and engaging with the US FDA for regulatory development.